Boehringer Ingelheim

Boehringer Ingelheim Named Official Animal Health Company Partner of the Atlanta Braves

Retrieved on: 
Thursday, April 4, 2024
Health, Atlanta Braves, Partnership, Boehringer Ingelheim, Atlanta, Truist Park, Love, Pet, Animal, Corporation, Boehringer Ingelheim Animal Health, Fine chemical

DULUTH, Ga., April 4, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the Atlanta Braves Foundation as the Official Animal Health Company partner, starting with the 2024 MLB season.

Key Points: 
  • DULUTH, Ga., April 4, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the Atlanta Braves Foundation as the Official Animal Health Company partner, starting with the 2024 MLB season.
  • Randolph Legg, President of Boehringer Ingelheim Animal Health USA, expressed his excitement about the partnership, "We are thrilled to join forces with the Atlanta Braves, a team that shares our commitment to community and excellence.
  • Boehringer Ingelheim Animal Health has a significant presence in the United States, providing a wide range of products and services to improve the health and wellbeing of animals.
  • Throughout the season, fans can expect multiple activations at the ballpark and in The Battery Atlanta, further strengthening the bond between the Atlanta Braves, Boehringer Ingelheim, and the community.

Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Retrieved on: 
Wednesday, March 27, 2024
AJRCCM, Medical research, ILD, AstraZeneca, ATS, Survival, Data science, Critical Care Medicine (journal), Partnership, Risk, Boehringer Ingelheim, Royal Brompton Hospital, Patient, American Journal, Lung, WRVS, Biopharmaceutical, Biomarker, Vital capacity, American Thoracic Society, Idiopathic pulmonary fibrosis, IPF, Clinical trial, Tralokinumab, Idiopathic disease, FVC

The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).

Key Points: 
  • The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).
  • The patient data from the trial was processed with Brainomix's e-Lung tool.
  • The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
  • WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival.

Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Retrieved on: 
Wednesday, March 27, 2024
AJRCCM, Medical research, ILD, AstraZeneca, ATS, Survival, Data science, Critical Care Medicine (journal), Partnership, Risk, Boehringer Ingelheim, Royal Brompton Hospital, Patient, American Journal, Lung, WRVS, Biopharmaceutical, Biomarker, Vital capacity, American Thoracic Society, Idiopathic pulmonary fibrosis, IPF, Clinical trial, Tralokinumab, Idiopathic disease, FVC

The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).

Key Points: 
  • The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).
  • The patient data from the trial was processed with Brainomix's e-Lung tool.
  • The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
  • WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival.

CKD Leaders Network Publishes New Thought Piece in Journal of Clinical Medicine

Retrieved on: 
Thursday, March 21, 2024
Research, Disease, FACC, Conditional sentence, TKG, Data science, CKD, Medicine, Patient, Author, Mortality, Manuscript, University, ICMJE, MPH, Network, Chronic kidney disease, Eli Lilly and Company, Multimedia, Marketing, Boehringer Ingelheim, Pharmaceutical industry

NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.

Key Points: 
  • NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.
  • "At The Kinetix Group, we are committed to improving care delivery through collaboration and innovation," said Anna Thomas , executive vice president.
  • CKD affects approximately 37 million individuals in the United States.
  • To learn more about CKD Leaders Network initiatives, contact [email protected] .

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
Thursday, March 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

Veeva Vault EDC Surpasses 1,000 Study Start Milestone

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, CDB, Organization, Data science, Clinical, Boehringer Ingelheim, Veeva Systems, EDC, Syneos Health, Data management, Health, Pharmaceutical industry

PLEASANTON, Calif., March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts. The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC. This underscores the ongoing shift to advanced clinical data management, with one top 20 biopharma recently migrating 25 studies and more organizations switching to Vault EDC for greater efficiency and speed.

Key Points: 
  • PLEASANTON, Calif., March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts.
  • The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC.
  • "Veeva Vault EDC simplifies complex data management for faster study builds and streamlined processes," said Richard Young, vice president, clinical data strategy at Veeva.
  • Vault EDC is part of Veeva Vault Clinical Data Management , bringing together EDC and Veeva Clinical Database (CDB) for next-generation clinical data management.

Veeva Vault EDC Surpasses 1,000 Study Start Milestone

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, CDB, Organization, Data science, Clinical, Boehringer Ingelheim, Veeva Systems, EDC, Syneos Health, Data management, Health, Pharmaceutical industry

BARCELONA, Spain, March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts. The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC. This underscores the ongoing shift to advanced clinical data management, with one top 20 biopharma recently migrating 25 studies and more organizations switching to Vault EDC for greater efficiency and speed.

Key Points: 
  • BARCELONA, Spain, March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts.
  • The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC.
  • "Veeva Vault EDC simplifies complex data management for faster study builds and streamlined processes," said Richard Young, vice president, clinical data strategy at Veeva.
  • Vault EDC is part of Veeva Vault Clinical Data Management , bringing together EDC and Veeva Clinical Database (CDB) for next-generation clinical data management.

1.9 Million Doses of NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): Donated by Boehringer Ingelheim Cares Foundation to Aid Shelter Dogs in Need

Retrieved on: 
Friday, March 15, 2024
Parasitism, Health, DSM-IV codes, Moxidectin, Coccidioides immitis, Boehringer Ingelheim, Tablet, Tick, Diarrhea, Dog, Lethargy, Boehringer, Breeding, Pet, Vomiting, Animal, Pharmaceutical industry

The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.

Key Points: 
  • The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.
  • The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms.
  • Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023.
  • NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.

NaturVet welcomes Phil Bramel as Chief Commercial Officer

Retrieved on: 
Wednesday, March 13, 2024
TSC, Target, Growth, Central Florida, PetSmart, University of Central Florida, Boehringer Ingelheim, University, CCO, Walmart, Family, Marketing, Warner–Lambert, J&J

TEMECULA, Calif, March 13, 2024 /PRNewswire-PRWeb/ -- NaturVet, the 30-year pioneer and present-day innovator of the pet health and wellness industry, is pleased to announce Phil Bramel as its new Chief Commercial Officer (CCO). Bramel brings a wealth of retail and sales expertise to the NaturVet family, with an illustrious 36-year career in various leadership roles within the pet health and wellness sector at companies such as Warner-Lambert, Pfizer, J&J, and Boehringer-Ingelheim. In his new role, Bramel will be responsible for driving sales and marketing strategies for NaturVet, including an expansion of the innovative brand's retail presence.

Key Points: 
  • In his new role, Bramel will be responsible for driving sales and marketing strategies for NaturVet, including an expansion of the innovative brand's retail presence.
  • "It is with great enthusiasm that we introduce Phil Bramel as our Chief Commercial Officer," said Geoff Granger , the CEO of The Garmon Corporation and NaturVet.
  • Click to Post: @NaturVet announces Phil Bramel as the new Chief Commercial Officer.
  • "It is an honor to join the NaturVet family, particularly at a time when the company stands poised for significant growth," said Bramel.

FTC Files Amicus Brief in Asthma Inhaler Patent Dispute

Retrieved on: 
Tuesday, April 2, 2024
The Orange Book, GSK plc, AstraZeneca, District court, Boehringer Ingelheim, Social media, Salbutamol, Policy, News, Blog, Motion, Judgement, Orange Book, Commission, Patent, FDA, Federal Trade Commission, Food, FTC

Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.

Key Points: 
  • Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.
  • The FTC’s amicus brief relates to a case brought by Teva against drugmaker Amneal after Amneal sought FDA approval to bring a generic version of asthma inhaler ProAir HFA to market.
  • Teva sued Amneal for patent infringement, arguing that Amneal’s patents infringe on Teva’s ProAir HFA patents.
  • The FTC’s amicus brief was filed in the U.S. District Court for the District of New Jersey.